The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to
and after total knee arthroplasty will significantly reduce the amount of bone loss.
In primary unilateral total knee arthroplasty patients, The investigator will examine the
effect of daily abaloparatide therapy in clinical osteoporotic patients beginning 3 months
pre-op and continued for a total of 15 months. This will be compared to osteopenic patients
receiving no therapy as well as previously published values in untreated osteoporotic
patients 12 months following Total Knee Arthroplasty (TKA).
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.